New mRNA flu vaccine for adults over 50 is 'more effective,' UW Medicine says

Key Points:

• A new mRNA flu vaccine called mFLUSIVA, developed with COVID-19 vaccine technology, is available for adults aged 50 and older and is nearly 30% more effective than traditional flu vaccines for this age group.
• The vaccine offers broader and more durable protection by producing antibodies that recognize a wider range of influenza viruses, addressing the weakened immune response in older adults due to immunosenescence.
• Washington state experienced significant flu-related deaths last season, with over 91% occurring in people aged 50 and older, highlighting the importance of vaccination in this demographic.
• The new vaccine is being distributed through pharmacies like CVS and Walgreens, but availability varies; individuals over 50 are advised to consult healthcare providers before vaccination, especially if they had severe reactions to COVID-19 mRNA vaccines.
• While the mRNA flu vaccine may cause stronger side effects such as fatigue and muscle aches, it is considered safe and effective, with Medicare likely covering it for those 65 and older, though private insurance coverage for ages 50-64 remains uncertain.